1887
  1. Home
  2. Eurosurveillance
  3. Volume 30, Issue 44, 06/Nov/2025
  4. Article
Rapid communication Open Access
Like 1
Download

Abstract

Older adults are at increased risk of severe chikungunya. Some countries advise against vaccinating ≥ 60 or ≥ 65-year-olds with the licenced live-attenuated vaccine (CHIKV LA, IXCHIQ), following severe adverse event (SAE) reports. A virus-like particle vaccine (CHIKV VLP, VIMKUNYA) is licensed in the United States (US), EU/EEA and the United Kingdom. Up to 31 August 2025, over 12,500 doses were administered in US and Germany; no SAEs in ≥ 65-year-olds were reported. Early post-authorisation data support its favourable safety profile in ≥ 65-year-olds.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2025.30.44.2500792
2025-11-06
2025-12-14
/content/10.2807/1560-7917.ES.2025.30.44.2500792
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/30/44/eurosurv-30-44-1.html?itemId=/content/10.2807/1560-7917.ES.2025.30.44.2500792&mimeType=html&fmt=ahah

References

  1. European Medicines Agency (EMA). IXCHIQ. Amsterdam: EMA. [Accessed: 3 Nov 2025]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/ixchiq
  2. European Medicines Agency (EMA). Search results for “VIMKUNYA”. Amsterdam: EMA. [Accessed: 3 Nov 2025]. Available from: https://www.ema.europa.eu/en/search?keywords=anyword&search_api_fulltext=vimkunya&f%5B0%5D=ema_search_entity_is_document%3ADocument
  3. Haute Autorité de Santé (HAS). Avis n° 2025.0022/DC/SESPEV du 25 avril 2025 du Collège de la HAS portant réévaluation de la recommandation relative au vaccin IXCHIQ suite à des signalements de pharmacovigilance. [Opinion No. 2025.0022/DC/SESPEV of April 25, 2025, from the HAS College concerning the reassessment of the recommendation regarding the IXCHIQ vaccine following pharmacovigilance reports]. Saint-Denis la Plaine: HAS. [Accessed: 3 Nov 2025]. French. Available from: https://www.has-sante.fr/upload/docs/application/pdf/2025-04/avis_25_avril_2025_reevaluation_ixchiq.pdf
  4. Centers for Disease Control and Prevention (CDC). Chikungunya vaccines. Atlanta: CDC; [Accessed: 3 Nov 2025]. Available from: https://www.cdc.gov/chikungunya/vaccines/index.html
  5. Kling K, Falman A, Branke L, Harder T, Feldt T, Löbermann M, et al. Beschluss der STIKO-Empfehlung zur Impfung gegen Chikungunya. [Resolution of the STIKO Recommendation on Vaccination Against Chikungunya]. Epidemiol Bull. 2025; (28):3-7. German. Available from: https://edoc.rki.de/bitstream/handle/176904/12816/EB-28-2025_10-25646-13274.pdf?sequence=1 https://doi.org/10.25646/13274 
  6. World Health Organization (WHO). Chikungunya. Geneva: WHO. [Accessed: 3 Nov 2025]. Available from: https://www.who.int/news-room/fact-sheets/detail/chikungunya
  7. World Health Organization (WHO). Chikungunya virus disease- Global situation. Geneva: WHO; 2025. Available from: https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON581
  8. European Centre for Disease Prevention and Control (ECDC). Seasonal surveillance for chikungunya virus disease in the EU/EEA, weekly report. Week 44, 2025. Stockholm: ECDC. [Accessed: 3 Nov 2025]. Available from https://www.ecdc.europa.eu/en/chikungunya-virus-disease/surveillance-and-updates/seasonal-surveillance
  9. Burt FJ, Chen W, Miner JJ, Lenschow DJ, Merits A, Schnettler E, et al. Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen. Lancet Infect Dis. 2017;17(4):e107-17.  https://doi.org/10.1016/S1473-3099(16)30385-1  PMID: 28159534 
  10. Weaver SC, Lecuit M. Chikungunya virus and the global spread of a mosquito-borne disease. N Engl J Med. 2015;372(13):1231-9.  https://doi.org/10.1056/NEJMra1406035  PMID: 25806915 
  11. World Health Organization (WHO). Chikungunya – La Réunion and Mayotte. Disease Outbreak News. 12 May 2025. Geneva: WHO. [Accessed: 3 Nov 2025]. Available from: https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON567?utm
  12. Micheleto JPC, Melo KA, Veloso FCS, Kassar SB, Oliveira MJC. Risk factors for mortality in patients with chikungunya: A systematic review and meta-analysis. Trop Med Int Health. 2025;30(4):235-45.  https://doi.org/10.1111/tmi.14088  PMID: 39894663 
  13. Hills SL, Sutter RA, Miller ER, Asturias EJ, Chen LH, Bell BP, et al. Surveillance for adverse events following use of live attenuated chikungunya vaccine, United States, 2024, and the associated public health response in 2024 and 2025. Euro Surveill. 2025;30(32):2500543.  https://doi.org/10.2807/1560-7917.ES.2025.30.32.2500543  PMID: 40814789 
  14. Kostev K, Wang Y, Singh R, Kalder M, Loosen SH, Roderburg C, et al. German longitudinal prescription database (LRx): Description of characteristics, use in pharmacoepidemiological research, and limitations
. Int J Clin Pharmacol Ther. 2024;62(1):20-8.  https://doi.org/10.5414/CP204485  PMID: 37969094 
  15. IQVIA. Unlock the keys to effective real-world data usage. [Accessed: 3 Nov 2025]. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/library/publications/unlock-the-keys-to-effective-real-world-data-usage.pdf
  16. European Medicines Agency (EMA). IXIARO (Japanese encephalitis vaccine, inactivated, adsorbed) – EPAR product information. Amsterdam: EMA; 2024. Available from: https://www.ema.europa.eu/en/documents/product-information/ixiaro-epar-product-information_en.pdf
  17. Public Health Agency of Canada. Guidance on the use of live-attenuated chikungunya vaccine IXCHIQ in persons 65 years of age and older. Ottawa: Government of Canada. [Accessed: 3 Nov 2025]. Available from: https://www.canada.ca/en/public-health/services/catmat/guidance-use-live-attenuated-chikungunya-vaccine-ixchiq-persons-65-years-older.html
  18. Haut Conseil de la santé publique. Recommandations sanitaires aux voyageurs 2025 [Health recommendations for travellers 2025]. Paris: Ministère du Travail, de la Santé, des Solidarités et des Familles. [Accessed: 3 Nov 2025]. Available from: https://sante.gouv.fr/IMG/pdf/recommandations_voyageurs_2025_27_juin.pdf
  19. Joint Committee on Vaccination and Immunisation. Chikungunya vaccine in UK travellers: JCVI advice. London: Department of Health and Social Care. [Accessed: 3 Nov 2025]. Available from: https://www.gov.uk/government/publications/chikungunya-vaccine-for-uk-travellers-jcvi-advice-16-july-2025/chikungunya-vaccine-in-uk-travellers-jcvi-advice
  20. Haute Autorité de Santé (HAS). Utilisation du vaccin IXCHIQ dans le contexte épidémique de chikungunya dans les territoires de La Réunion et de Mayotte. Avis validé 27 février 2025; actualisation mars 2025. [Use of the IXCHIQ vaccine in the context of chikungunya epidemics in the territories of Réunion and Mayotte. opinion approved February 27, 2025; Updated March 2025]. Saint-Denis la Plaine: HAS. [Accessed: 3 Nov 2025]. Available from: https://www.has-sante.fr/upload/docs/application/pdf/2025-03/avis_-_utilisation_du_vaccin_ixchiq_dans_le_contexte_epidemique_de_chikungunya_dans_les_territoires_de_la_reunion_et_de_mayo.pdf
  21. Schneider M, Narciso-Abraham M, Hadl S, McMahon R, Toepfer S, Fuchs U, et al. Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2023;401(10394):2138-47.  https://doi.org/10.1016/S0140-6736(23)00641-4  PMID: 37321235 
  22. US Food and Drug Administration (USFDA). VIMKUNYA. Silver Spring; USFDA. [Accessed: 30 Oct 2025]. Available from: https://www.fda.gov/vaccines-blood-biologics/vimkunya
  23. Medicines and Healthcare products Regulatory Agency. Vimkunya vaccine approved to prevent disease caused by the chikungunya virus in people 12 years of age and older. London: GOV.UK. [Accessed: 30 Oct 2025]. Available from: https://www.gov.uk/government/news/vimkunya-vaccine-approved-to-prevent-disease-caused-by-the-chikungunya-virus-in-people-12-years-of-age-and-older
  24. Tindale LC, Richardson JS, Anderson DM, Mendy J, Muhammad S, Loreth T, et al. Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2025;405(10487):1353-61.  https://doi.org/10.1016/S0140-6736(25)00372-1  PMID: 40158524 
  25. Bachmann MF, van Damme P, Lienert F, Schwarz TF. Virus-like particles: a versatile and effective vaccine platform. Expert Rev Vaccines. 2025;24(1):444-56.  https://doi.org/10.1080/14760584.2025.2508517  PMID: 40387310 
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error